News

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

In the past, many women born with a heart condition were told they would not be able to birth children safely.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Asian individuals with out-of-hospital cardiac arrest have similar rates of bystander cardiopulmonary resuscitation as White individuals, but have lower survival rates, according to a new study.

Asian individuals experience poorer outcomes after out-of-hospital cardiac arrest in the U.S. compared with white individuals, despite similar rates of bystander CPR.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.

Melissa Magwire talks about why diabetes is a population health problem and a unique program at Saint Luke's that is helping patients across the nation.